论文部分内容阅读
目的探讨血清胸苷激酶1(STK1)在诊断肝细胞肝癌(肝癌)中的临床意义。方法采用增强发光免疫点印迹法检测100例肝癌患者(A组)和13例肝血管瘤患者(B组)STK1含量,并以STK1值≤2pmol/L作为参考值对检测结果进行分析。结果 A组STK1值高于B组[(1.94±1.55)pmol/L vs.(0.85±0.44)pmol/L](P<0.05)。A组36例的STK1值>2pmol/L,B组所有病例的STK1值均≤2pmol/L。结论检测STK1有助于肝癌的诊断及肝脏良恶性疾病的鉴别。
Objective To investigate the clinical significance of serum thymidine kinase 1 (STK1) in the diagnosis of hepatocellular carcinoma (HCC). Methods The levels of STK1 in 100 patients with hepatocellular carcinoma (A group) and 13 patients with hepatic hemangioma (Group B) were detected by enhanced luminescence immunofluoresence blotting. The detection results were analyzed with STK1 value ≤2 pmol / L as the reference value. Results The value of STK1 in group A was higher than that in group B [(1.94 ± 1.55) pmol / L vs. (0.85 ± 0.44) pmol / L] (P <0.05). In group A, 36 patients had STK1 values> 2 pmol / L, and all patients in group B had STK1 values ≤2 pmol / L. Conclusion Detection of STK1 contributes to the diagnosis of liver cancer and the identification of benign and malignant liver diseases.